Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

ASND stock hub

Ascendis Pharma A/S has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

ASNDis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

14.8B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

ASND

In the news

Latest news · ASND

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E54.5

P25 12.3P50 18.4P75 33.1

Trailing P/E25.8

P25 14.9P50 23.2P75 38.5

ROE332.7

P25 -105.6P50 -46.5P75 -3.1

ROIC-0.4

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All ASND market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

187

Groups with data

Currency

EUR

Showing 187 of 187 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001612042
Company name	Ascendis Pharma A/S
Country	Denmark
Country code	US
Cusip	04351P101
Employees	1,189
Employees Change	172%
Employees Change Percent	16.91
Enterprise value	$15.2B
Exchange	NASDAQ
Financial currency	EUR
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2015-01-28
Isin	DK0060615755
Last refreshed	2026-05-10
Market cap	$14.8B
Market cap category	Large-Cap
Price	$239
Price currency	USD
Rev Per Employee	839,567.94x
Sector	Healthcare
Sic	2834
Symbol	ASND
Website	https://ascendispharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	3.86%
EV Earnings	26.58x
EV Sales Forward	9.82x
EV/FCF	286.4x
EV/Sales	15.22x
FCF yield	0.36%
Forward P/E	54.48x
P/B ratio	26.17x
P/E ratio	25.77x
P/S ratio	14.85x
PS Forward	9.58x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-0.84%
EBITDA Margin	-0.31%
FCF margin	5.32%
Gross margin	89.04%
Gross Profit	$888.8M
Gross Profit Growth	145.11%
Gross Profit Growth Q	174.56%
Gross Profit Growth3 Y	127.55%
Gross Profit Growth5 Y	65.02%
Net Income	$571.8M
Net Income Growth Quarters	8%
Net Income Growth Years	3%
Pretax Margin	-19.32%
Profit Margin	57.28%
Profit Per Employee	$480,917
ROA	-0.3
Roa5y	-22.72
ROCE	-0.83
ROE	332.7
ROIC	-0.44

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS Growth Quarters	7
EPS Growth Years	3
Revenue Growth	134.82x
Revenue Growth Q	144.27x
Revenue Growth Quarters	7x
Revenue Growth Years	5x
Revenue Growth3 Y	123.13x
Revenue Growth5 Y	175.31x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.56
Assets	$2.3B
Cash	$660.5M
Current Assets	$1.3B
Current Liabilities	$1.3B
Debt	$1B
Debt Equity	$1.84
Debt FCF	$19.48
Equity	$562.6M
Interest Coverage	-0.07
Liabilities	$1.7B
Long Term Assets	$986.2M
Long Term Liabilities	$418.4M
Net Cash	$-373.4M
Net Cash By Market Cap	$-2.52
Net Debt Equity	$0.66
Net Debt FCF	$7.04
Tangible Book Value	$558.4M
Tangible Book Value Per Share	$9.05
WACC	7.06

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1
Inventory Turnover	0.31
Net Working Capital	$-76.9M
Quick ratio	0.68
Working Capital	$-5.1M
Working Capital Turnover	$63.27

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-5.28%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
All Time High	250.3
All Time High Change	-4.64%
All Time High Date	2026-05-08
All Time Low	216.2
All Time Low Change	10.38%
All Time Low Date	2026-04-29
ATR	10.29
Beta	0.49
Beta1y	8.17
High	250.3
High52	250.3
High52 Date	2026-05-08
High52ch	-4.64%
Low	236.2
Low52	216.2
Low52 Date	2026-04-29
Low52ch	10.38%
RSI	42.52
RSI Monthly	0
RSI Weekly	0
Sharpe ratio	-0.87x
Sortino ratio	-1.19
Total Return	-5.28%
Tr1w	8.03%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	14
Analyst Count Top	6
Analyst Price Target Top	$278
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$0.21
Earnings Revenue Estimate	318,050,000x
Earnings Revenue Estimate Growth	199.58x
Operating Income	$-8.4M
Operating margin	-0.84
Price target	$284
Price Target Change	$18.82
Price Target Change Top	$16.56

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	61,779,750%
Float Percent	99.47%
Net Borrowing	-32,397,678.2
Shares Institutions	26.21%
Shares Out	62,111,595
Shares Qo Q	5.78%
Shares Yo Y	5.28%
Short Ratio	6.47
Short Shares	7.22

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-86.4M
Average Volume	895,357.07x
Bv Per Share	9.12
CAPEX	$-17.9M
Ch1w	8.03
Change	-3.04%
Change From Open	-3.04
Close	246.1
Days Gap	0
Depreciation Amortization	5,343,399.8
Dollar Volume	160,913,641.1
Earnings Date	2026-05-07
Earnings Time	bmo
EBIT	$-8.4M
EBITDA	$-3.1M
EPS	$9.26
F Score	4
FCF	$53.1M
FCF EV Yield	0.35x
FCF Per Share	$0.85
Financing CF	20,199,470
Fiscal Year End	December
Founded	2,006
Graham Number	43.58731
Graham Upside	-81.74
Income Tax	$-764.7M
Investing CF	-16,758,907
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-11
Net CF	63,296,437
Next Earnings Date	2026-08-06
Open	246.1
Optionable	Yes
P FCF Ratio	279.4
P OCF Ratio	212.5
Position In Range	17.37
Ppne	160,287,843.1
Price Date	2026-05-08
Ptbv Ratio	26.55
Relative Volume	0.75x
Revenue	998,246,281x
SBC By Revenue	13.97x
Share Based Comp	139,477,689
Tax By Revenue	-76.6x
Volume	674,238

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does ASND pay a dividend?

Capital-return profile for this ticker.

Ownership

Who owns ASND?

Insider, institutional, and short-interest positioning.

Institutional ownership

+26.2%

Float: +99.5% of shares outstanding

Insider ownership

n/a

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

ASND momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

42.5

Neutral momentum band

Price vs 200-day MA

n/a

50/200-day relationship not available

Beta (5Y)

0.48

Less volatile than the market

Sharpe ratio

-0.87

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About ASND

Hub-level FAQ points readers to the deeper analysis pages.

What is the current ASND stock rating?

Ascendis Pharma A/S is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ASND analysis?

The full report lives at /stocks/ASND/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for ASND?

The latest report frames ASND around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the ASND page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.